岡山医学会 Acta Medica Okayama 0030-1558 125 1 2013 メサラジン坐薬調製の工夫と臨床経験 29 33 EN Keiko Funagakure Syuzi Horita Terutaka Hamaoka Takeshi Tasaka Hiroshi Tatibana Takako Murakami Tatuya Toyokawa Eiji Sato Jun Tomoda Ulcerative proctitis (UP) is a prevalent condition associated with increased morbidity, and topical mesalazine (5-aminosalicylic acid [5-ASA]) is known to inhibit the inflammatory processes in UP. We successfully devised mesalazine suppositories, in which 250mg mesalazine was equally distributed and remained stable for at least 2 weeks. We evaluated the effect of using mesalazine suppositories twice a day (BID) on two UP patients. The results demonstrated that mesalazine suppositories were efficacious, well tolerated and safe for the long-term maintenance of UP remission. No potential conflict of interest relevant to this article was reported.